Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study

2003 ◽  
Vol 21 (23) ◽  
pp. 4402-4406 ◽  
Author(s):  
Bertrand Coiffier ◽  
Nicolas Mounier ◽  
Serge Bologna ◽  
Christophe Fermé ◽  
Hervé Tilly ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Adult Patients ◽  
Urate Oxidase ◽  
Induction Treatment ◽  
Tumor Lysis ◽  
Hodgkin's Lymphomas ◽  
Elevated Lactate

Purpose: Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin’s lymphomas (NHLs). Usual prophylaxis and treatment of hyperuricemia consist of hydration, alkalinization, and administration of allopurinol. This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy. Patients and Methods: A total of 100 patients from Groupe d’Etude des Lymphomes de l’Adulte centers, with diffuse large B-cell lymphoma (n = 79); anaplastic large-cell lymphoma (n = 6); peripheral T-cell lymphoma (n = 8); transformation of indolent lymphoma (n = 5); Burkitt’s lymphoma (n = 1); and lymphoblastic lymphoma (n = 1) were enrolled from May 2001 to June 2002. Before chemotherapy, 66% of patients had elevated lactate dehydrogenase (LDH), including 28% with LDH above 1,000 U/mL. Eleven percent of patients were hyperuricemic (uric acid [UA] > 450 mmol/L or > 7.56 mg/dL). Rasburicase 0.20 mg/kg/d intravenously for 3 to 7 days was started the day before or at day 1 of chemotherapy. UA levels were measured 4 hours after rasburicase injection, then daily during treatment. Results: All patients responded to rasburicase, as defined by normalization of UA levels maintained during chemotherapy. The control of UA was obtained within 4 hours after the first injection of the drug. Creatinine levels and other metabolites were also controlled with the administration of rasburicase. No patient exhibited increased creatinine levels or required dialysis during chemotherapy. Conclusion: Rasburicase is the treatment of choice to control UA and prevent tumor lysis syndrome in adult patients with aggressive NHL.

Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report

2016 ◽  
Vol 23 (3) ◽  
pp. 235-239 ◽  
Author(s):  
Varinder Kaur ◽  
Arjun Swami
Keyword(s):  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Tumor Lysis ◽  
Mantle Cell ◽  
Hodgkin's Lymphomas

Mantle cell lymphoma accounts for 5–7% of all non-Hodgkin’s lymphomas. Under the current WHO classification, it is categorized as an indolent B cell lymphoma, but has an aggressive clinical course. New insights into leukemogenic molecular pathways of mantle cell lymphoma have uncovered unique therapeutic targets. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma. Long-term studies have shown that grade 3 or 4 adverse events are infrequent. Asymptomatic lymphocytosis is frequently seen with ibrutinib use in mantle cell lymphoma; however, tumor lysis syndrome is an extremely rare complication. To date, only two patients with ibrutinib-associated tumor lysis syndrome in mantle cell lymphoma have been described in a long-term follow-up study. Both patients met laboratory criteria for tumor lysis syndrome, however, but did not develop clinical tumor lysis syndrome. We, here describe a patient with relapsed mantle cell lymphoma who developed clinical tumor lysis syndrome with ibrutinib monotherapy.

scholarly journals Spontaneous Tumor Lysis Syndrome in the Setting of B-Cell Lymphoma

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
Mateusz Opyrchal ◽  
Travis Figanbaum ◽  
Amit Ghosh ◽  
Vincent Rajkumar ◽  
Sean Caples
Keyword(s):  
Cell Lymphoma ◽  
Early Recognition ◽  
Tumor Lysis Syndrome ◽  
Delayed Diagnosis ◽  
B Cell Lymphoma ◽  
Tumor Cell Death ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Underlying Malignancy ◽  
Spontaneous Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) presenting in absence of chemotherapy is a rare occurrence. One of the true oncological emergencies, it can lead to significant morbidity and mortality. TLS is a phenomena usually associated with tumor cell death after treatment. The etiology of the spontaneous TLS is not well understood, which complicates the diagnosis. TLS is well known to oncologists but physicians outside of this specialty have little or no experience with this condition. Early recognition and treatment are the keys to limiting the sequela of the condition. Spontaneous tumor lysis syndrome is rare but presents added risks to the patient because of the potential for delayed diagnosis and no benefit of pretreatment. Diagnosis may be further delayed because this may be the first symptom of underlying malignancy. Therefore, it is imperative that all clinicians are familiar with the syndrome to assure timely recognition.

scholarly journals Rituxan-Induced Tumor Lysis Syndrome in a Patient With Diffuse Large B-Cell Lymphoma

Cureus ◽  
2021 ◽  
Author(s):  
Saffa Iftikhar ◽  
Waleed Khokher ◽  
Joan Gekonde ◽  
Nithin Kesireddy ◽  
Prabath Mudiyanselage
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Tumor Lysis ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Case Report: Primary dural based diffuse large B-Cell lymphoma in a 14 year-old boy

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 78 ◽  
Author(s):  
Sunil Munakomi ◽  
Binod Bhattarai ◽  
Balaji Srinivas ◽  
Iype Cherian
Keyword(s):  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Mass Effect ◽  
Large Cell ◽  
Clinical Prognosis ◽  
Timely Fashion ◽  
Dural Lymphoma ◽  
Hodgkin's Lymphomas ◽  
Oncology Unit ◽  
High Index Of Suspicion

Primary dural lymphoma is a subentity of primary leptomeningeal lymphoma which represents 0.1% of all non-Hodgkin’s lymphomas. Only five cases have been reported so far. We report a very rare case of primary dural-based lymphoma in a 14 year-old boy presenting with mass effect. The patient was managed with excision of the lesion and removal of the involved bone. Post-operatively, the patient showed good recovery. He was then referred to the oncology unit for further chemo- and radiation therapy. A high index of suspicion should therefore be kept in order to diagnose the condition in a timely fashion and then plan for appropriate management since diffuse large cell lymphoma has a relatively benign clinical prognosis.

scholarly journals A rare case of nodular lymphocyte predominant Hodgkin lymphoma, which developed 5 years after successful treatment of diffuse large B-cell lymphoma

2021 ◽  
Vol 20 (1) ◽  
pp. 162-167
Author(s):  
M. A. Senchenko ◽  
D. S. Abramov ◽  
A. E. Rudneva ◽  
E. V. Volchkov ◽  
G. A. Nasirdinova ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
World Literature ◽  
Cell Lymphoma ◽  
Pediatric Population ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Frequent Relapses ◽  
Ann Arbor ◽  
Hodgkin's Lymphomas

Nodular lymphocyte predominant Hodgkin lymphoma (NLHLP) – B-cell lymphoma, which has been historically added to the group of Hodgkin's lymphomas, despite the peculiarities of the clinical course, treatment and prognosis, as well as morphological and immunophenotypical differences. In 75% of cases, the disease is detected at early stages (I–II according to Ann Arbor classification), has an indolent course and a favorable prognosis with 10-years an overall survival rate, more than 80%. Despite this, with long-term follow-up and the development of frequent relapses, transformation into diffuse large-cell B-cell lymphoma (DCBCL) or T-lymphocyte/histiocyte-rich DCBCL can occur, isolated cases in children. In the world literature, there are isolated cases of the development of NLHLP after treatment of DCBKL in adults, while among the pediatric population, cases have not been described. This article presents a clinical case of DCBKL in a 10-year-old child who, 5 years after the end of treatment, developed nodular Hodgkin's lymphoma with lymphocytic predominance. The patient's parents agreed to use the information, including the child's photo, in scientific research and publications. 

Sign in / Sign up

Export Citation Format

Share Document